{'fraction_non_alphanumeric': 0.02320887991927346, 'fraction_numerical': 0.008072653884964682, 'mean_word_length': 5.613333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Kinetics and duration of action of ranitidine on gastric secretion and its effect on pancreatic secretion in duodenal ulcer patients.

Inhibitory effects of ranitidine, a new H2-receptor antagonist, and cimetidine on histamine and pentagastrin-induced gastric secretion have been compared in duodenal ulcer patients. Compared with cimetidine, ranitidine was found to be about 6-8 times a more potent inhibitor of gastric acid secretion, the inhibition of histamine-induced secretion being competitive, whereas that of pentagastrin-induced secretion not competitive. Ranitidine was an effective inhibitor of pentagastrin-induced secretion 8-12 h after administration. When given in a dose inhibiting gastric secretion by over 90%, it did not affect pancreatic secretion induced by secretin and pancreozymin. The availability of ranitidine, a more powerful inhibitor of gastric secretion, provides an opportunity of a treatment alternative to cimetidine, for peptic ulcer and related diseases.